Page last updated: 2024-09-05

enzastaurin and Bone Cancer

enzastaurin has been researched along with Bone Cancer in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bovée, JV; Briaire-de Bruijn, IH; Gelderblom, H; Herpers, B; van de Water, B; van Oosterwijk, JG; van Ruler, MA	1
Bradford, D; Bufill, J; Casey, EM; Fisher, W; Hanna, N; Harb, W; Latz, JE; Li, X; Nattam, S; Patel, J; Wu, J	1
Dudek, AZ; Ericson, ME; Farassati, F; Gallus, NJ; Jasinski, P; Terai, K; Zwolak, P	1

Trials

1 trial(s) available for enzastaurin and Bone Cancer

Article	Year
Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11 Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Placebos; Pleural Neoplasms; Survival Rate; Treatment Outcome	2010

Article

Year

Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11

Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Carboplatin; Double-Blind Method; Female; Glutamates; Guanine; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Placebos; Pleural Neoplasms; Survival Rate; Treatment Outcome

2010

Other Studies

2 other study(ies) available for enzastaurin and Bone Cancer

Article	Year
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Chondrosarcoma; Dasatinib; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Indoles; Male; MCF-7 Cells; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-fyn; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Suppressor Protein p53; Young Adult	2013
Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis. Investigational new drugs, 2008, Volume: 26, Issue:1 Topics: Animals; Apoptosis; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, SCID; Neovascularization, Pathologic; Osteoclasts; Pain; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; ras Proteins; Signal Transduction; Tumor Burden	2008

Article

Year

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.

British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Chondrosarcoma; Dasatinib; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Indoles; Male; MCF-7 Cells; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-fyn; Pyrimidines; Signal Transduction; src-Family Kinases; Thiazoles; Tumor Suppressor Protein p53; Young Adult

2013

Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.

Investigational new drugs, 2008, Volume: 26, Issue:1

Topics: Animals; Apoptosis; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Female; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, SCID; Neovascularization, Pathologic; Osteoclasts; Pain; Protein Kinase C; Protein Kinase C beta; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; ras Proteins; Signal Transduction; Tumor Burden

2008